Valeant Pharmaceuticals International Inc., of Laval, Quebec, said it obtained the requisite lender approval for an amendment to its credit facility to reduce the interest coverage maintenance covenant to 2x for additional headroom, to provide additional flexibility to sell assets, to permit the issuance of secured notes with shorter maturities to repay term loans and to permit the incurrence of other debt to repay term loans.